NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
Clinical Trials
14 trialsNCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06217042 2024-01-22
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
Fudan University
Phase 3 Not yet recruiting
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT00030732 2019-05-15
Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
Swiss Cancer Institute
Phase 3 Completed
NCT02117479 2019-03-26
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Incyte Corporation
Phase 3 Terminated
NCT02119663 2018-02-13
A Study of Ruxolitinib in Pancreatic Cancer Patients
Incyte Corporation
Phase 3 Terminated
NCT01077427 2017-11-17
HEAT
Klinikum der Universitaet Muenchen, Grosshadern
Phase 3 Unknown
NCT02854072 2016-11-22
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
Samsung Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT00417209 2016-06-03
PAPRIKA
Sanofi
Phase 3 Completed
NCT00634725 2015-12-11
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT00425360 2013-08-26
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00032175 2013-06-26
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00440167 2012-07-09
Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
Ludwig-Maximilians - University of Munich
Phase 3 Unknown